Your COPD is considered to be moderate. Your FEV1 is between 30% and 49% of the normal predicted values, and your FEV1/FVC is less than 70%. In this stage, you may experience shortness of breath ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

For this reason, two contemporaneous studies of the oral PDE-4 inhibitor roflumilast tested its added benefit in COPD patients treated with salmeterol or tiotropium. Patients with moderate to ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

FDA grants breakthrough designation to tezepelumab for COPD Tezepelumab has received an FDA breakthrough therapy designation as a maintenance treatment for patients with moderate to very severe ...

HealthDay News — There is a bidirectional association between rheumatoid arthritis (RA) and chronic obstructive pulmonary ...

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

The study involved 804 COPD patients exhibiting type 2 inflammation ... therapy significantly reduced the annualised rate of moderate/severe exacerbations compared to placebo, with subjects ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.